pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy
Biogen
Biogen is a pharma organization headquartered in VISAKHAPATNAM, IN. Primary therapeutic focus areas include Relapsing-Remitting Multiple Sclerosis, Spinal Muscular Atrophy, systemic lupus erythematosus, IgA nephropathy,
225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 225 Binney Street, Cambridge, MA 02142, US
- Employees
- 7,534
- Programs
- 31
- Drugs
- 45
- Patents
- 25
BIIB019 (Daclizumab)
Phase 3 · small molecule · Relapsing-Remitting Multiple Sclerosis
BIIB019 (Daclizumab) for Relapsing-Remitting Multiple Sclerosis is a Phase 3 program (small_molecule) at Biogen with 1 ClinicalTrials.gov record(s).
Internal code 205MS303
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Biogen
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Relapsing-Remitting Multiple Sclerosis
- Status
- terminated
- Trials
- 1